- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Anti-Nausea Drug Approved
Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to treat nausea and vomiting among adults undergoing cancer chemotherapy.
Nausea and vomiting are common side effects of chemotherapy that can persist for days after the drugs are given. Prolonged bouts of these reactions can lead to weight loss, dehydration and malnutrition, the agency said Wednesday in a news release.
Varubi was evaluated by some 2,800 participants in three clinical trials, administered in combination with other anti-nausea drugs. The most common side effects included low white blood cell count, hiccups, loss of appetite and dizziness.
The FDA said Varubi should not be taken by people who are taking the drug thioridazine, which is commonly prescribed to treat schizophrenia.
Varubi is marketed by Tesaro Inc., based in Waltham, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During MidlifeTUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
-
Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer ScreeningIn guidelines that may encourage more women to get...
- December 10, 2024
